Preview Mode Links will not work in preview mode

Sep 28, 2023

Featuring a slide presentation and related discussion from Dr Paul G Richardson, including the following topics:

  • Biologic rationale for targeting protein degradation pathways as a therapeutic approach in multiple myeloma (MM); mechanism of action of CELMoDs (0:00)
  • Published efficacy and safety findings with iberdomide-containing combination regimens from the Phase I/II CC-220-MM-001 study (6:30)
  • Emerging data with mezigdomide/dexamethasone for relapsed/refractory MM (13:22)
  • Early results with and ongoing investigations of mezigdomide/dexamethasone in combination with a proteasome inhibitor (29:54)

CME information and select publications